This study was designed to determine the effect of dexamethasone treatment on peripheral blood lymphocyte counts and subpopulations in premature infants with bronchopulmonary dysplasia (BPD).
Bronchopulmonary dysplasia (BPD) is a chronic lung disease associated with mechanical ventilation in premature infants and a common cause of morbidity in the neonatal intensive care unit. The incidence of BPD is Յ40% among infants with respiratory distress syndrome who require mechanical ventilation. 1 Treatment with intravenous dexamethasone has been shown to shorten the duration of mechanical ventilation in premature infants, 2 and to improve pulmonary function. 3 However, dexamethasone therapy has many potential side effects in premature infants, including hyperglycemia, 4 hypertension, 5 cardiomyopathy, 6 adrenal suppression, [7] [8] [9] and gastrointestinal bleeding. 10 Dexamethasone has been shown to cause neutrophilia and eosinopenia 11, 12 in addition to inhibition of colony formation of the hematopoietic progenitor cells in in vitro experiments. 13 Fuenfer et al. studied the effects of various corticosteroids on the bactericidal activity of neutrophils and demonstrated that dexamethasone produced variable, short-term inhibitory effects within the neutrophils responsible for the bactericidal activity. 14 In premature infants, dexamethasone treatment has been shown to cause a mild decrease in serum Ig levels. 15 Dexamethasone and other glucocorticosteroids have been reported to cause lymphocytopenia and altered T cell function in adults and children. 16 -18 However, the effect of dexamethasone on blood lymphocyte subpopulations in premature infants has not been reported. The purpose of this study was to determine the effect of dexamethasone on total leukocytes and relative and absolute lymphocyte counts in premature infants before, during, and after therapy with dexamethasone for BPD. We hypothesized that a commonly used dexamethasone treatment protocol would cause significant and sustained alterations in lymphocyte subpopulations in premature infants.
METHODS

Patient Characteristics
The inclusion criteria for the patients in the study were: gestational age of Ͻ34 weeks, postnatal age of between 2 and 8 weeks, depen-
dency on mechanical ventilation since birth, an inspired oxygen fraction of Ͼ0.4, and changes consistent with Northway's criteria for BPD on chest radiographs. The patients were selected for dexamethasone therapy by the attending physician in our neonatal intensive care unit, based on clinical criteria independent of the study. Exclusion criteria were: major congenital malformations, cytomegalovirus infection, sepsis, and patent ductus arteriosus requiring treatment with indomethacin. Informed consent was obtained from a parent for all participants, and the study was approved by our hospital's Institutional Review Board. A total of 14 patients were recruited during the time period of February to November 1995. Of these 14 patients, one family revoked their consent. One other participant was excluded due to inability to obtain a blood sample after discontinuation of dexamethasone. All infants were treated with diuretics, theophylline, and/or aerosolized albuterol at the time of the study.
Dexamethasone Treatment and Blood Samples
The dexamethasone protocol of Cummings et al. was used. 19 The 6-week treatment course started with 0.5 mg/kg per day intravenously for 3 days followed by 0.3 mg/kg per day for 4 days, with the dose decreasing by 10% every week for a total of 6 weeks of therapy. Blood samples for peripheral leukocyte count and lymphocyte subpopulations were obtained before starting dexamethasone therapy (day 0) and on days 3 and 10 of treatment. A fourth blood sample was obtained 2 weeks after dexamethasone treatment ended (day 56). Blood specimens were collected by venipuncture or from an indwelling arterial catheter. The blood was collected between 8 and 10 AM to minimize the effect of diurnal variations in peripheral leukocyte profile. Blood was placed in EDTA-treated tubes and immediately transported to the immunology laboratory. One of the coauthors (L. V. R.) performed the B cell, T cell, and T cell subset analysis. He was blinded to the identity of the patient and to the day of dexamethasone treatment. Infants with BPD who were able to be extubated while on dexamethasone therapy were defined as responders to dexamethasone. Infants who remained ventilator dependent at the completion of the initial dexamethasone course or who received more than one course were identified as nonresponders.
Immunophenotyping
Immunofluorescent analysis of T cells, B cells, and T cell subsets (CD4
ϩ and CD8 ϩ ) in peripheral blood was conducted on unseparated blood using human monoclonal antibodies and flow cytometry. Monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) were obtained from Becton Dickinson (San Diego, CA). Irrelevant human monoclonal Ig conjugated with the respective fluorochromes were used as isotypic controls.
Blood samples (100 l) were incubated with individual fluorescent-labeled antibodies and controls for 20 minutes at room temperature in the dark. Combinations of FITC-and PE-conjugated antibodies were used to produce double staining. After staining, the cells were suspended in 2 ml of 1ϫ fluorescence-activated cell sorter lysing solution (Becton Dickinson) to lyse the erythrocytes and subsequently incubated at room temperature in the dark for 10 minutes. The tubes were centrifuged and washed in phosphate-buffered saline, fixed in 0.5% paraformaldehyde, and stored at 4°C before examination by flow cytometry.
Flow Cytometry
The percentage of positive cells in each cell preparation was determined using a flow cytometer (FACScan; Becton Dickinson Immunocytometry Systems, San Jose, CA) in a standard configuration provided by the manufacturer. Autocomp software using Calibrate beads (Becton Dickinson) was used to standardize instrument electronics before each analysis. All analyses were performed with a Consort 30 computer (HP 9000, model 310; Hewlett Packard, North Hollywood, CA) and Simulset software (Becton Dickinson). Fluorescence data were expressed as dual parameter histograms of green (FITC) versus orange (PE) fluorescence. Four quadrant analyses, with markers set on the isotype controls, were used to determine the percentage of positive cells for each set of monoclonal antibodies.
Statistical Analysis
Pretreatment peripheral blood leukocyte subsets served as self controls and were compared with the values obtained on days 3 and 10 of treatment and 2 weeks after the discontinuation of dexamethasone (day 56). Fisher's protected least square difference post hoc testing was used for multiple comparisons .The Stat View data analysis and presentation system by Abacus Concepts (Berkeley, CA) was used to analyze the repeated measures of analysis of variance. Values are expressed as either mean Ϯ SEM or SD.
RESULTS
A total of 12 premature infants with a mean birth weight ( Ϯ SD) of 870 Ϯ 174 gm and a mean gestational age of 27 Ϯ 1.7 weeks were studied. There was no difference in the gender or racial distribution of patients. Among the premature infants who received dexamethasone, 10 of 12 patients (83%) were able to be weaned off the mechanical ventilation. The dexamethasone treatment protocol was started at a mean of 18.4 Ϯ 9.5 days postnatal age. None of the study infants had bacteremia before the initiation of dexamethasone, and only two infants were treated with vancomycin and gentamicin for presumed sepsis while on dexamethasone. Urine cytomegalovirus screening before starting dexamethasone was not routine during the study period and was performed in only six patients.
The total leukocyte counts and the percentages of neutrophils, lymphocytes, and monocytes before, during, and 2 weeks after the discontinuation of dexamethasone are shown in Table 1 . Compared with day 0 (self controls), the total white blood cell count and neutrophil counts were significantly higher on days 3 and 10 of dexamethasone therapy ( p ϭ 0.0001). The percentage of lymphocytes was significantly lower on days 3 and 10 of dexamethasone therapy ( p ϭ 0.0001) but recovered to above the pretreatment value after the completion of glucocorticoid therapy. The percentage of mononuclear cells was unchanged during and after dexamethasone therapy.
The T cell, B cell, and T cell subset (CD4 ϩ and CD8 ϩ ) percentages during the dexamethasone weaning regimen are shown in Table  2 . The percentage of B cells on day 10 of steroid therapy was significantly higher compared with the pretreatment value ( p ϭ 0.0001) and returned to the pretreatment value 2 weeks after dexamethasone was stopped. Although the percentage of T cells on days 3 and 10 of dexamethasone was significantly lower ( p ϭ 0.004), it returned to baseline 2 weeks after dexamethasone was discontinued. In contrast, the significant decline in the percentage of CD4 ϩ cells seen on days 3 and 10 of steroid therapy persisted even after completion of dexamethasone therapy ( p ϭ 0.002). Although the CD8 ϩ lymphocyte subset percentage was unchanged on days 3 and 10 of dexamethasone, it was significantly higher after stopping dexamethasone ( p ϭ 0.001).
The absolute numbers of B cells, T cells, and T cell subsets (CD4 ϩ and CD8 ϩ ) are shown in Table 3 . Compared with the pretreatment value, the absolute number of T cells declined significantly on day 10 of dexamethasone therapy ( p ϭ 0.0001). However, the B cells demonstrated a significant increase 3 days after the commencement of steroids ( p ϭ 0.0065), reverting to the pretreatment value on day 10. There was a significant decrease in the absolute number of CD4 ϩ cells on day 10 of dexamethasone therapy that persisted 2 weeks after treatment was stopped ( p ϭ 0.04). The absolute number of CD8 ϩ cells remained unchanged during and after dexamethasone therapy. The CD4/CD8 ratio was significantly reduced on days 3 and 10 of treatment, and this pronounced decline reached its nadir on day 56, when the infants were no longer treated with dexamethasone ( p ϭ 0.00013).
DISCUSSION
T cell subpopulations have been studied very little in premature infants. We have shown that the commonly used regimen of dexamethasone for BPD induced significant changes in CD4 as well as in the CD4/CD8 ratio during and after the cessation of therapy. Perhaps, this significant, selective decline in CD4 T cells observed in our study may partially explain the beneficial clinical effect of dexamethasone in BPD. Our data also suggest that dexamethasone had no effect on the CD8 cells. However, the effects of dexamethasone on neutrophil and lymphocyte function 14,16 -18 may also predispose these premature infants to infections, particularly with viral or fungal pathogens.
The leukocytosis and neutrophilia noted in our patient population during dexamethasone treatment are consistent with findings observed in other studies. 12 Ballow et al. 20 reported CD4 and CD8 numbers and CD4/CD8 ratios for 36 infants with a birth weight of Ͻ1500 gm. The mean CD4/CD8 ratio was Ն2.5 for infants of a postnatal age of Յ3 months. Data on T cell subpopulations in healthy infants are also lacking. For infants of Յ2 months of age (excluding neonates), mean/median CD4/CD8 ratios were 2.4 and 3.8, respectively, in two recent studies. 21, 22 The absolute CD4 counts ranged from 2590/l (in the very low birth weight infants, at age 1.5 months) to 3500/l (in healthy infants, aged 1 week to 2 months). These results are very similar to those in our study in the infants before treatment with dexamethasone (Table 3) .
Dexamethasone therapy in babies with BPD complicated by respiratory failure is associated with improved ventilator weaning and increased frequency of endotracheal extubation. This beneficial effect on the lungs and airways of infants with BPD has been presumed to be due to the anti-inflammatory effect of dexamethasone with regard to the inflammatory pathogenesis of BPD. 23 There are numerous reports to support the role of inflammation in the pathogenesis of BPD. For example, lipid mediators, such as leukotrienes, are elevated in lavage fluid from intubated infants with BPD, and there are limited data on increased cytokines in tracheal fluid from infants with BPD. 24 Eosinophil cationic protein has been shown recently to be elevated in premature infants who go on to BPD. 25 There are also some data showing decreased cytokine levels in lavage fluid from BPD infants treated with dexamethasone. 23 Because CD4 cells are a major source of proinflammatory cytokines, we speculate that our findings of decreased CD4 numbers in BPD babies treated with dexamethasone may provide a partial explanation for the decrease in inflammatory mediators in the airways and lungs. The interaction of the various pathways of inflammation has been reviewed in detail elsewhere; one recent review provides an excellent summary of the role of inflammation in the pathogenesis of BPD, including the effect of T cell-derived cytokines on other inflammatory mediators. 26 A similar case has been made for the role of CD4 cells in asthmatic inflammation. Recently, it was reported that CD4 cell numbers were decreased in bronchial biopsies from asthmatics treated with oral prednisolone. 27 The authors speculated that CD4 cells may play an important part in asthmatic inflammation, and we believe our data suggest an analogous role for CD4 cells in BPD.
Cell-mediated immunity has been cited as the most important component of immune responses that counter infection due to enveloped respiratory viruses. 28 Hall et al. 29 demonstrated that long-term steroid use in children resulted in prolonged shedding of respiratory syncytial virus, which was proposed to be due to uninhibited replication from an impaired cell-mediated immune response. It is likely that the pronounced changes noted in CD4 ϩ cells and in the CD4/CD8 ratio in premature infants treated with dexamethasone may explain the mechanism of action of steroids by decreasing the inflammatory mediators and also may account for the increased predilection of these infants to viral infections, particularly respiratory syncytial virus.
T lymphocytes are crucial for normal immune functions, especially with regard to viral and fungal pathogens. The degree of CD4 suppression found in our study is analogous to the findings in human immunodeficiency virus infection. 30 We are unaware of any studies of the incidence of infection with viral or fungal pathogens in premature infants treated with dexamethasone compared with BPD controls. Papille et al. have shown that early dexamethasone treatment for BPD is associated with an increased incidence of nosocomial infection with Staphylococcus epidermidis infection. 31 Over the past 3 years, we have witnessed an upsurge in neonatal candidiasis in our intensive care unit. This led us to analyze the risk factors for Candida sepsis in 204 premature infants weighing Ͻ1250 gm and born between 1996 and 1998. In 57 of 204 (28%) infants with neonatal candidiasis, initiation of dexamethasone at an age of Ͻ14 days ( p ϭ 0.05) was associated with Candida sepsis (our unpublished data). It has also been reported that, for very low birth weight infants with BPD, viral infections such as respiratory syncytial virus are a significant source of morbidity. Our study suggests that infants treated with dexamethasone may be more susceptible to infections due to CD4 suppression.
Further studies will be needed to test the association of dexamethasone-induced CD4 lymphopenia with an increased rate of severity of infection in infants with BPD and the significance of an increased B lymphocyte count during the dexamethasone regimen shown in our small series of premature infants. 
